semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 16.0-60.0,  Sickle Cell Disease Patients with sickle cell disease, subtype Hgb SS, SC, or SB disease who are on chronic transfusion therapy for a prior stroke or those patients who were intolerant of hydroxyurea therapy or were being treated with hydroxyurea therapy and were complicated by at least one of the following Stroke or central nervous system event lasting longer than 24 hours Frequent vaso-occlusive pain episodes, defined as ≥ 3 per year severe enough to interfere with the patient's normal daily function or require medical attention in the clinic, emergency room, acute care center, or hospital Recurrent episodes of priapism, defined as ≥ 2 per year requiring emergency room visits Acute chest syndrome with recurrent hospitalizations, defined as ≥ 2 lifetime events Red-cell alloimmunization (≥ 2 antibodies) during longterm transfusion therapy Bilateral proliferative retinopathy with major visual impairment in at least one eye Osteonecrosis of 2 or more joints Sickle cell nephropathy Stage I or II sickle lung disease
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 6.0-20.0,  Sickle Cell-hemoglobin SS Disease Vaso-occlusive Crisis Patient with SS or S-Beta sickle cell disease aged more than 6 years old and less then 20 years old Hospitalised since less then 24 hours for severe vaso-occlusive crisis (either peripheric localisation or thoracic crisis) with morphinic requirements according to local pain management protocol With a signed informed consent from the patient or his legal representative if the patient is under 18 years old Benefiting of the French social security system  Patient that has already participated in the study Oxygen requirements, pneumonia, acute chest syndrome or other condition necessitating non invasive ventilation on admission No understanding of spirometry or ventilation techniques Other condition that forbid the use of non invasive ventilation or spirometry as defined by french consensus conference (2006) on non invasive ventilation
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 3.0-40.0,  Sickle Cell Disease Pain Crisis Recurrent Anemia Infection Death patients with symptoms associated with sickle cell disease those able to receive laying-on-of-hands every weekday for 1 year those able to receive conventional medical treatment whenever necessary those able to receive blood test at the beginning, after 6 month and after 1 year  those who wish to use other complementary and alternative therapies along with laying-on-of-hands
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 5.0-999.0,  Sickle Cell Disease Vaso-occlusive Crisis Genotypes Hb SS, Hb SC, sickle β°-thalassemia, sickle β+ -thalassemia Pain consistent with vaso-occlusive crisis (clinical judgment) and not attributable to other causes Serum CRP ≥5.0 mg/L at time of screening Fever defined as oral temperature ≥38.0°C at time of screening Age ≥5 years  New or suspected new pulmonary infiltrate diagnosed by chest radiography Females who are nursing, pregnant or intend to become pregnant Renal dysfunction defined as a creatinine level >1.2 mg/dL for subjects aged 18 or less or a creatinine level >1.5 mg/dL for subjects over the age of 18 Hepatic dysfunction (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] >3 × upper limit of normal) Acute neurologic dysfunction Any medical condition for which transfusion may be needed imminently, and/or hemoglobin <5 g/dL Red blood cell transfusion within 30 days prior to screening Parenteral or oral corticosteroid therapy (inhaled steroids acceptable) within 7 days prior to screening
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Sickle Cell Disease Sickle Cell Anemia Anemia, Sickle Cell All volunteer subjects must be at least 18 years of age and have provided informed, written consent for participation in this study. in the study is determined prior to enrollment on the basis of the following and   Laboratory values obtained within the preceding 60 days are sufficient for screening purposes. for SCD Cohort Males or females 18 years of age or older Diagnosis of sickle cell disease (any form; electrophoretic or HPLC documentation is required) for SCD Cohort Chronic scheduled transfusions Current known pregnancy or lactation Hemoglobin <5.0 g/dL; however, subjects may return for repeat evaluation at a later date Currently smoking and unable to refrain from smoking for 24 hours Subjects previously known to have conditions that may independently affect hemolytic rate Infection or sepsis in the 2 weeks prior to screening Autoimmune hemolytic anemia Systemic lupus erythematosus (SLE) Myelodysplastic disorders, leukemia, or lymphoma Hereditary spherocytosis or elliptocytosis Severe cardiac valve dysfunction (e.g. AS, MS) or prosthetic heart valve recipients for Controls In order to validate the methodology for endogenous CO measurement, initially for each enrolled study subject with sickle cell disease (up to the first 30 subjects), we will recruit an African-American healthy control subject of the same gender, within 3 years of age older or younger than the matched subject with SCD. Additionally, 20 healthy control subjects will be enrolled for adenosine and any functionally or chemically related molecules blood testing, and venous blood gas testing only, to compare against subjects with sickle cell disease. Their participation in this study will consist of one blood draw of 11 mL for research laboratory testing for Controls Current pregnancy or lactation Serum ALT values >80 IU/L Serum creatinine >2.0 mg/dL Hemoglobin <11.2 g/dL for females, <13.7 for males; however, subjects may return for repeat evaluation at a later date Currently smoking Subjects with any known form of sickle cell disease (sickle trait will NOT be excluded) Subjects with any other known forms of hemolytic anemia
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Sickle Cell Disease Sickle Cell Anemia Regadenoson ARM Diagnosis of sickle cell anemia confirmed by hemoglobin analysis Ages 18 to 70 years Subjects must have laboratory indices as outlined by the protocol Reliable IV access as determined by physician Sickle Cell Controls ARM Diagnosis of sickle cell anemia confirmed by hemoglobin analysis Ages 18 to 70 years Sickle Cell CEU ARM Diagnosis of sickle cell anemia, confirmed by hemoglobin analysis Males and females age 18-70 years Healthy Control ARM African American  Regadenoson ARM Hospitalization, emergency department visit or self-reported crisis within last 2 weeks for any reason or 4 weeks from acute chest syndrome Current physician diagnosis of active asthma (within last 12 months) or current use of asthma medications Second or third degree AV block or sinus node dysfunction Known or suspected right to left sided cardiac shunts History of a bleeding diathesis History of clinically overt stroke History of severe hypertension not adequately controlled with anti-hypertensive medications Receiving chronic anti-coagulation or anti-platelet therapy History of metastatic cancer
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  Sickle Cell Disease FOR WITH CELL IN PAIN 1. Age 18 years or older. 2. Diagnosis of sickle cell anemia: 1. Diagnosis of sickle cell disease (electrophoresis or HPLC documentation of hemoglobin SS, SC, S-beta-thalassemia or other hemoglobinopathies causing sickle cell disease is required). 2. Acute onset pain crisis in a distribution typical for that subject, onset within the last 7 days and for which hospitalization and parenteral narcotic pain treatment are required. 3. Ability to provide informed written consent  FOR WITH CELL IN PAIN 1. Pregnancy. 2. History of non-trivial injury, burns, surgery or skin ulcers on the arms. 3. Carrier of drug resistant bacteria that normally requires isolation while visiting a hospital. 4. Administration of any of the following drugs within the last 14 days Phosphodiesterase-5 inhibitors (sildenafil, vardenafil, tadalafil) Endothelin-1 receptor blockers (bosentan, sitaxentan, ambrisentan, tezosentan) Nitric oxide donors (nitroglycerin, nitroprusside, nitrates) 5. Ingestion of caffeine within the 12 hours before the start of the study appointment, or tobacco use within the 30 days before the study appointment. 6. Diagnosis with any of the following chronic diseases or conditions Uncontrolled high blood pressure (systolic blood pressure must not be greater than 160 mmHg or diastolic blood pressure greater than 90 mmHg) Uncontrolled high cholesterol (total cholesterol must not be greater than 240 mg/dL) Uncontrolled diabetes (must not have both a documented history of diabetes and random blood glucose of greater than 200 mg/dL) Chronic kidney disease (serum creatinine must not be greater than 2 mg/dL) Coronary artery disease Peripheral vascular disease 7. Received a blood transfusion within 7 days of the study procedure. CELL IN STATE FOR WITH CELL IN STATE: 1. Age 18 years or older. 2. Diagnosis of sickle cell anemia: a.Diagnosis of sickle cell disease (electrophoresis or HPLC documentation of hemoglobin SS, SC, S-beta-thalassemia or other hemoglobinopathies causing sickle cell disease is required). 3. Ability to provide informed written consent
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Connective Tissue Musculoskeletal Pain for chronic low back pain subjects back pain that has disrupted activity for more than half the days in the past 12 months. for restricted hamstring subjects 90 test of more than 20 degrees for systemic scleroderma subjects physician diagnosis for joint hyperlaxity subjects Beighton test score of 7 or higher  for all subjects surgery or scars in thighs or low back neurological or major psychiatric disorder bleeding disorders acute systemic infection pregnancy
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Clear Cell Renal Cell Carcinoma Stage IV Renal Cell Cancer AJCC v7 Patient must have pathologically confirmed renal cell carcinoma with a clear cell component; pure papillary and chromophobe histologies are excluded; there must be pathologic confirmation of metastatic disease in the resected metastasectomy specimen Patient must have undergone nephrectomy or partial nephrectomy to remove primary renal cell carcinoma (at any time in the past) Patient must have undergone surgical resection to remove one or more sites of metastatic disease, with successful removal of all known sites 2-12 weeks prior to randomization; any number of prior metastasectomies may have been performed in the past, so long as the most recent procedure was within the 12 weeks of registration; the most recent procedure may be nephrectomy for a renal primary tumor Patients with synchronous disease at initial diagnosis must have metastatic (M1) disease (American Joint Committee on Cancer [AJCC] 7th edition T1-4N0-1M1) Positive surgical margins are permitted if the surgeon confirms complete resection of gross metastatic disease, and post-operative scans are negative Patients presenting with metachronous disease may have distant metastases, regional lymph node or renal bed recurrence; recurrences at a partial nephrectomy resection site are not eligible if it is the only site of disease Patients presenting with tumors within the kidneys (multiple synchronous or single/multiple metachronous) are not eligible if there are no extrarenal sites of disease (i.e. potential multifocal primary disease) Patient must have no evidence of disease on post-operative imaging A computed tomography (CT) of the chest must be obtained within 4 weeks prior to randomization with or without contrast A CT of the abdomen/pelvis must be obtained within 4 weeks prior to randomization with intravenous (IV) contrast (oral contrast may be added at the radiologist's discretion); an magnetic resonance imaging (MRI) of the abdomen/pelvis with gadolinium may be substituted for the CT if the CT with IV contrast is contra-indicated
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 12.0-60.0,  Sickle Cell Disease Sickle Cell Anemia Sickle Cell Disorders Hemoglobin S Disease Sickling Disorder Due to Hemoglobin S Males and females between 12 and 60 years of age Diagnosis of SCD, type Hb SS or Hb S-B0 Thalassemia At least 1 episode of SCD pain crisis, acute chest syndrome, other acute SCD complications, or leg ulcers in the 12 months prior to screening Not being treated with Hydroxyurea (HU); if HU treatment has been previously administered and then discontinued, at least 3 months must have elapsed since last dose of HU If subject has been transfused in the 3 months prior to screening, then Hb A level < 20% at screening Baseline Hb F level obtained within 14 days prior to randomization Able to swallow tablets Able and willing to give informed consent and/or assent If subject is a woman of child-bearing potential (WCBP), she must have a negative serum pregnancy test within 14 days of first dose of HQK-1001 and a negative urine pregnancy test prior to dosing on Day 1 If a subject is a WCBP, she must agree to use an effective form of contraception starting at screening and for one month after HQK-1001 discontinuation  Assigned to a regular transfusion program Use of erythropoiesis stimulating agents within 90 days prior to screening An SCD pain crisis or SCD-related acute complication within 3 weeks prior to randomization More than 5 SCD pain crisis or SCD-related acute complications within 12 months prior to screening Pulmonary hypertension requiring therapy ALT or AST > 3x ULN Serum creatinine > 1.5x ULN Serum amylase levels > 1.5x ULN Serum lipase level > 1.5x ULN A serious, concurrent illness that would limit ability to complete or comply with the study requirements